Recently, Yuanda Shuyang’s new production base achieved the first export of Human Immunoglobulin for Intravenous Injection (hereinafter referred to as "IVIG") to South American countries. As a leading exporter of blood products in China, Yuanda Shuyang has been deeply cultivating the international market over 20 years, with its products being sold to more than 10 countries and regions in Asia, Eastern Europe, the Middle East, Latin America, etc. The new production base of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. is located at No.888 Antai 5th Road, West Hi-Tech District, Chengdu, covering an area of 180 mu with a total investment of over 2 billion yuan. The new base is designed with high standards, benchmarking against international first-class enterprises. Its standards are in line with China's GMP and meet the EU GMP standards. The new base has a strong production capacity, which can simultaneously produce three major categories of blood products, including human albumin, immunoglobulin, and coagulation factors, covering the production demand of the whole product chain. The new base has a large single-unit production capacity, and the annual plasma output of the single-unit can reach 1,500 tons, expanding to 2,000 tons. In order to cast the enterprise brand of "Shuyang Quality", Yuanda Shuyang has built a demonstration base of intelligent digital factory in the field of sterile preparations through the integration of informationization and industrialization, based on the framework of Industry 4.0.

According to MRB statistics, IVIG is the largest product in the global production and sales of  blood products , accounting for 49.1%, and becoming a rising trend year by year. After the COVID-19 pandemic, a number of diagnostic and treatment programs and expert consensus pointed out that IVIG can be used to treat the seriously ill of COVID-19, which boosted the demand for IVIG in the short term. In the long run, the COVID-19 pandemic has increased the awareness of doctors and patients on IVIG, and the demand for IVIG may be further increased. In the future, Yuanda Shuyang will further expand its international business to bring safe and reliable medicines to patients around the world, make Chinese brands go global, and continue to contribute to the cause of human life and health in China.